Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN019 in active rheumatoid arthritis
NCT04038970Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Nov 2019
- Primary completion
- Jul 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of KN019 in rheumatoid arthritis (RA), sponsored by Alphamab Oncology. Started Nov 2019; status: completed.
02
Drugs
KN019
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04038970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04038970.